CR10019A - Derivados de mestastina y sus usos - Google Patents
Derivados de mestastina y sus usosInfo
- Publication number
- CR10019A CR10019A CR10019A CR10019A CR10019A CR 10019 A CR10019 A CR 10019A CR 10019 A CR10019 A CR 10019A CR 10019 A CR10019 A CR 10019A CR 10019 A CR10019 A CR 10019A
- Authority
- CR
- Costa Rica
- Prior art keywords
- activity
- suppressing
- present
- hormone secretion
- metastin
- Prior art date
Links
- 230000000694 effects Effects 0.000 abstract 5
- 230000028327 secretion Effects 0.000 abstract 4
- 239000005556 hormone Substances 0.000 abstract 3
- 229940088597 hormone Drugs 0.000 abstract 3
- 206010027476 Metastases Diseases 0.000 abstract 2
- 206010028980 Neoplasm Diseases 0.000 abstract 2
- 150000001413 amino acids Chemical class 0.000 abstract 2
- 201000011510 cancer Diseases 0.000 abstract 2
- 230000005907 cancer growth Effects 0.000 abstract 2
- 230000001456 gonadotroph Effects 0.000 abstract 2
- KAHDONZOCXSKII-NJVVDGNHSA-N kisspeptin Chemical class C([C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCC(N)=O)C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C=CC=CC=1)C(N)=O)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H]1N(CCC1)C(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]1N(CCC1)C(=O)[C@H]1N(CCC1)C(=O)[C@H]1N(CCC1)C(=O)[C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)CN)[C@@H](C)O)C1=CN=CN1 KAHDONZOCXSKII-NJVVDGNHSA-N 0.000 abstract 2
- 230000009401 metastasis Effects 0.000 abstract 2
- 230000004936 stimulating effect Effects 0.000 abstract 2
- 102000013599 Kisspeptins Human genes 0.000 abstract 1
- 108010012048 Kisspeptins Proteins 0.000 abstract 1
- 230000004071 biological effect Effects 0.000 abstract 1
- 239000008280 blood Substances 0.000 abstract 1
- 210000004369 blood Anatomy 0.000 abstract 1
- 239000000470 constituent Substances 0.000 abstract 1
- 239000003163 gonadal steroid hormone Substances 0.000 abstract 1
- 230000001568 sexual effect Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4702—Regulators; Modulating activity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/04—Drugs for genital or sexual disorders; Contraceptives for inducing labour or abortion; Uterotonics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/06—Antiabortive agents; Labour repressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/26—Androgens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/30—Oestrogens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4702—Regulators; Modulating activity
- C07K14/4703—Inhibitors; Suppressors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Diabetes (AREA)
- Endocrinology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Toxicology (AREA)
- Reproductive Health (AREA)
- Immunology (AREA)
- Hematology (AREA)
- Gynecology & Obstetrics (AREA)
- Obesity (AREA)
- Pregnancy & Childbirth (AREA)
- Heart & Thoracic Surgery (AREA)
- Epidemiology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Cardiology (AREA)
- Neurology (AREA)
- Hospice & Palliative Care (AREA)
- Oncology (AREA)
- Emergency Medicine (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2005370388 | 2005-12-22 | ||
| JP2006275843 | 2006-10-06 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CR10019A true CR10019A (es) | 2008-07-29 |
Family
ID=37846230
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CR10019A CR10019A (es) | 2005-12-22 | 2008-05-26 | Derivados de mestastina y sus usos |
Country Status (29)
| Country | Link |
|---|---|
| US (1) | US7960348B2 (enExample) |
| EP (1) | EP1963362B1 (enExample) |
| JP (2) | JP4653840B2 (enExample) |
| KR (1) | KR101368607B1 (enExample) |
| AR (1) | AR058584A1 (enExample) |
| AU (1) | AU2006328333B2 (enExample) |
| BR (1) | BRPI0619399B8 (enExample) |
| CA (1) | CA2634647C (enExample) |
| CR (1) | CR10019A (enExample) |
| CY (1) | CY1112353T1 (enExample) |
| DK (1) | DK1963362T3 (enExample) |
| ES (1) | ES2375038T3 (enExample) |
| GE (1) | GEP20115356B (enExample) |
| HR (1) | HRP20110851T1 (enExample) |
| IL (1) | IL190888A (enExample) |
| JO (1) | JO2799B1 (enExample) |
| MA (1) | MA30060B1 (enExample) |
| ME (1) | ME01015B (enExample) |
| MY (1) | MY151967A (enExample) |
| NO (1) | NO341879B1 (enExample) |
| NZ (1) | NZ568322A (enExample) |
| PE (1) | PE20071141A1 (enExample) |
| PL (1) | PL1963362T3 (enExample) |
| PT (1) | PT1963362E (enExample) |
| RS (1) | RS52007B (enExample) |
| RU (1) | RU2430107C2 (enExample) |
| SI (1) | SI1963362T1 (enExample) |
| TW (1) | TWI386417B (enExample) |
| WO (1) | WO2007072997A1 (enExample) |
Families Citing this family (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20050090420A (ko) | 2002-12-26 | 2005-09-13 | 다케다 야쿠힌 고교 가부시키가이샤 | 메타스틴 유도체 및 이의 용도 |
| CA2518541C (en) | 2003-03-12 | 2013-05-21 | Takeda Pharmaceutical Company Limited | Gonadal function improving agents |
| WO2006001499A2 (en) * | 2004-06-25 | 2006-01-05 | Takeda Pharmaceutical Company Limited | Metastin derivatives and use thereof |
| US8404643B2 (en) | 2005-12-22 | 2013-03-26 | Takeda Pharmaceutical Company Limited | Metastin derivatives and use thereof |
| TWI386417B (zh) | 2005-12-22 | 2013-02-21 | Takeda Pharmaceutical | 轉移抑素衍生物及其用途 |
| US20090093615A1 (en) * | 2005-12-22 | 2009-04-09 | Takeda Pharmaceutical Company Limited | Metastin derivatives and use thereof |
| JO3048B1 (ar) | 2006-10-25 | 2016-09-05 | Takeda Pharmaceuticals Co | مشتقات متاستين واستخدامها |
| EP2277900A4 (en) * | 2008-04-24 | 2011-08-03 | Takeda Pharmaceutical | METASTINE DERIVATIVE AND ITS USE |
| JP5698977B2 (ja) | 2008-07-30 | 2015-04-08 | 武田薬品工業株式会社 | メタスチン誘導体およびその用途 |
| UY32367A (es) * | 2008-12-29 | 2010-07-30 | Takeda Pharmaceutical | Agente preventivo/terapéutico contra el cáncer |
| MA33910B1 (fr) * | 2009-12-22 | 2013-01-02 | Takeda Pharmaceutcal Company Ltd | Formulation à libération prolongée |
| EA021663B1 (ru) * | 2010-06-25 | 2015-08-31 | Такеда Фармасьютикал Компани Лимитед | Композиция с замедленным высвобождением, способ ее получения и способ лечения рака |
| EP2755690B1 (en) | 2011-08-04 | 2020-04-01 | Merck Sharp & Dohme B.V. | Kisspeptide-pentasaccharide conjugates |
| WO2014010614A1 (ja) | 2012-07-12 | 2014-01-16 | 武田薬品工業株式会社 | マイクロカプセル粉末の製造方法 |
| WO2015112703A1 (en) * | 2014-01-22 | 2015-07-30 | The Johns Hopkins University | Compositions and methods for treating diabetes |
| JP6253146B2 (ja) * | 2014-02-04 | 2017-12-27 | 国立大学法人山口大学 | 新規なペプチド誘導体及びこれを含有する医薬 |
| WO2018060501A2 (en) | 2016-09-30 | 2018-04-05 | Myovant Sciences Gmbh | Methods of treating uterine fibroids and endometriosis |
| IL311335A (en) | 2016-09-30 | 2024-05-01 | Sumitomo Pharma Switzerland Gmbh | Methods for treating female infertility |
| WO2019007383A1 (zh) | 2017-07-05 | 2019-01-10 | 凯惠科技发展(上海)有限公司 | 一种肽类化合物、其应用及含其的组合物 |
Family Cites Families (44)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL74827A (en) | 1984-05-21 | 1989-06-30 | Salk Inst For Biological Studi | Peptides active as gnrh antagonists and pharmaceutical compositions containing them |
| MX9100717A (es) | 1990-08-24 | 1992-04-01 | Syntex Inc | Antagonistas de la bradiquinina |
| JPH09169735A (ja) | 1995-10-19 | 1997-06-30 | Takeda Chem Ind Ltd | キノリン誘導体、その製造法および用途 |
| AU7333496A (en) | 1995-10-19 | 1997-05-07 | Takeda Chemical Industries Ltd. | Quinoline derivatives as gnrh antagonists |
| JP2000510453A (ja) | 1996-04-19 | 2000-08-15 | ノボ ノルディスク アクティーゼルスカブ | 成長ホルモン遊離特性を有する化合物 |
| CA2283299A1 (en) | 1997-03-07 | 1998-09-11 | Human Genome Sciences, Inc. | 186 human secreted proteins |
| JP4486187B2 (ja) | 1998-10-27 | 2010-06-23 | 武田薬品工業株式会社 | 新規ｇ蛋白質共役型レセプター蛋白質、そのｄｎａおよびそのリガンド |
| US6528054B1 (en) | 1998-12-28 | 2003-03-04 | Corixa Corporation | Compositions and methods for the therapy and diagnosis of breast cancer |
| WO2001000228A1 (de) | 1999-06-28 | 2001-01-04 | Basf Aktiengesellschaft | Verfahren zur verhinderung von tumorwachstum |
| AU779019B2 (en) | 1999-08-02 | 2005-01-06 | Archer-Daniels-Midland Company | Metabolic engineering of amino acid production |
| AU1889101A (en) | 1999-12-17 | 2001-06-25 | Takeda Chemical Industries Ltd. | Process for producing kiss-1 peptide |
| CZ20023567A3 (cs) | 2000-03-29 | 2003-11-12 | Corixa Corporation | Sloučeniny a způsoby pro terapii a diagnostiku karcinomu plic |
| EP1273658A4 (en) * | 2000-03-30 | 2004-08-11 | Takeda Chemical Industries Ltd | NEW PROTEIN, THEIR DNA AND METHOD FOR THE PRODUCTION THEREOF |
| US7834141B1 (en) | 2000-03-31 | 2010-11-16 | Theresa Siler-Khodr | Non-mammalian GnRH analogs and uses thereof in tumor cell growth regulation and cancer therapy |
| RU2311920C2 (ru) | 2000-09-20 | 2007-12-10 | Корикса Корпорейшн | Композиции и способы для лечения и диагностики рака легких |
| JP2003026601A (ja) | 2000-11-29 | 2003-01-29 | Takeda Chem Ind Ltd | 医薬組成物およびその製造法 |
| JP2002320496A (ja) | 2001-02-26 | 2002-11-05 | Takeda Chem Ind Ltd | 新規マウス型ＫｉＳＳ−１レセプタータンパク質およびそのＤＮＡ |
| WO2002085399A1 (fr) | 2001-04-20 | 2002-10-31 | Takeda Chemical Industries, Ltd. | Preparations contenant un peptide |
| CN1509336A (zh) | 2001-05-17 | 2004-06-30 | 株式会社岛津制作所 | 肽的制备方法 |
| ATE360034T1 (de) * | 2001-09-19 | 2007-05-15 | Takeda Pharmaceutical | Antikörper gegen metastin und dessen verwendung zur diagnose von schwangerschaft |
| CA2472423A1 (en) | 2002-01-11 | 2003-07-24 | Takeda Chemical Industries, Ltd. | Process for producing kiss-1 peptide |
| JP2003300906A (ja) | 2002-04-12 | 2003-10-21 | Daiichi Fine Chemical Co Ltd | がん転移抑制因子の安定化 |
| MXPA05004380A (es) | 2002-10-25 | 2005-11-23 | Paradigm Therapeutics Ltd | Mamiferos gpr54 knock out y metodos de investigacion que los utilizan. |
| JP4804714B2 (ja) | 2002-12-26 | 2011-11-02 | 武田薬品工業株式会社 | メタスチン誘導体およびその用途 |
| KR20050090420A (ko) * | 2002-12-26 | 2005-09-13 | 다케다 야쿠힌 고교 가부시키가이샤 | 메타스틴 유도체 및 이의 용도 |
| US6800611B2 (en) * | 2003-01-06 | 2004-10-05 | Takeda Chemical Industries, Ltd. | Metastin derivatives and their use |
| KR100595364B1 (ko) | 2003-02-20 | 2006-07-03 | 재단법인 목암생명공학연구소 | Ｌｋ8 단백질을 유효성분으로 포함하는 항암제 |
| CA2518541C (en) * | 2003-03-12 | 2013-05-21 | Takeda Pharmaceutical Company Limited | Gonadal function improving agents |
| EP1464652A1 (en) | 2003-04-02 | 2004-10-06 | Institut National De La Sante Et De La Recherche Medicale (Inserm) | GPR54 receptor agonist and antagonist useful for the treatment of gonadotropin related diseases |
| US20050002935A1 (en) | 2003-04-17 | 2005-01-06 | Vincent Ling | Use of B7-H3 as an immunoregulatory agent |
| US20050026224A1 (en) | 2003-04-28 | 2005-02-03 | Follettie Maximillian T. | Methods and compositions for modulating G-protein coupled receptor 54 |
| WO2004101747A2 (en) | 2003-05-07 | 2004-11-25 | The General Hospital Corporation | Identification and use of gpr54 and its ligands for reproductive disorders and contraception |
| WO2004106289A1 (en) | 2003-05-30 | 2004-12-09 | Prozymex A/S | Protease inhibitors |
| RU2333221C2 (ru) | 2003-11-03 | 2008-09-10 | Бейцзин Санбио Байотек Ко., Лтд. | Рекомбинантный белок, обладающий противораковым действием, кодирующий его ген и его применение |
| CA2544473C (en) | 2003-11-03 | 2013-08-13 | Beijing Sunbio Biotech Co., Ltd. | A recombinant protein having an anti-cancer effect, its encoding gene and uses thereof |
| WO2005095973A2 (en) | 2004-03-25 | 2005-10-13 | Bayer Healthcare Ag | Diagnostics and therapeutics for diseases associated with g-protein coupled receptor 54 (gpr54) |
| WO2006001499A2 (en) * | 2004-06-25 | 2006-01-05 | Takeda Pharmaceutical Company Limited | Metastin derivatives and use thereof |
| US7725869B1 (en) * | 2005-04-07 | 2010-05-25 | Xilinx, Inc. | Method and apparatus for modeling multiple instances of an electronic circuit using an imperative programming language description |
| WO2007084211A2 (en) | 2005-11-11 | 2007-07-26 | The General Hospital Corporation | Use of gpr54 ligands for treatment of reproductive disorders, proliferative disorders, and for contraception |
| TWI386417B (zh) | 2005-12-22 | 2013-02-21 | Takeda Pharmaceutical | 轉移抑素衍生物及其用途 |
| US20090099334A1 (en) * | 2005-12-22 | 2009-04-16 | Takeda Pharmaceutical Company Limited | Metastin derivatives and use thereof |
| US8404643B2 (en) * | 2005-12-22 | 2013-03-26 | Takeda Pharmaceutical Company Limited | Metastin derivatives and use thereof |
| US20090093615A1 (en) * | 2005-12-22 | 2009-04-09 | Takeda Pharmaceutical Company Limited | Metastin derivatives and use thereof |
| JO3048B1 (ar) | 2006-10-25 | 2016-09-05 | Takeda Pharmaceuticals Co | مشتقات متاستين واستخدامها |
-
2006
- 2006-12-20 TW TW095147852A patent/TWI386417B/zh active
- 2006-12-20 AR ARP060105651A patent/AR058584A1/es active IP Right Grant
- 2006-12-21 PE PE2006001686A patent/PE20071141A1/es active IP Right Grant
- 2006-12-21 ME MEP-2009-175A patent/ME01015B/me unknown
- 2006-12-21 KR KR1020087012506A patent/KR101368607B1/ko active Active
- 2006-12-21 HR HR20110851T patent/HRP20110851T1/hr unknown
- 2006-12-21 NZ NZ568322A patent/NZ568322A/en unknown
- 2006-12-21 US US12/158,251 patent/US7960348B2/en active Active
- 2006-12-21 JP JP2008529406A patent/JP4653840B2/ja not_active Expired - Fee Related
- 2006-12-21 PL PL06843555T patent/PL1963362T3/pl unknown
- 2006-12-21 EP EP06843555A patent/EP1963362B1/en active Active
- 2006-12-21 CA CA2634647A patent/CA2634647C/en active Active
- 2006-12-21 SI SI200631152T patent/SI1963362T1/sl unknown
- 2006-12-21 ES ES06843555T patent/ES2375038T3/es active Active
- 2006-12-21 PT PT06843555T patent/PT1963362E/pt unknown
- 2006-12-21 DK DK06843555.1T patent/DK1963362T3/da active
- 2006-12-21 RS RS20110437A patent/RS52007B/sr unknown
- 2006-12-21 BR BRPI0619399A patent/BRPI0619399B8/pt not_active IP Right Cessation
- 2006-12-21 WO PCT/JP2006/326176 patent/WO2007072997A1/en not_active Ceased
- 2006-12-21 GE GEAP200610770A patent/GEP20115356B/en unknown
- 2006-12-21 RU RU2008125063/04A patent/RU2430107C2/ru active
- 2006-12-21 AU AU2006328333A patent/AU2006328333B2/en not_active Ceased
- 2006-12-21 MY MYPI20082169 patent/MY151967A/en unknown
- 2006-12-21 JO JO2006486A patent/JO2799B1/en active
-
2008
- 2008-04-15 IL IL190888A patent/IL190888A/en active IP Right Grant
- 2008-05-26 CR CR10019A patent/CR10019A/es unknown
- 2008-06-10 NO NO20082595A patent/NO341879B1/no unknown
- 2008-06-18 MA MA31044A patent/MA30060B1/fr unknown
-
2010
- 2010-08-17 JP JP2010182482A patent/JP5298087B2/ja active Active
-
2011
- 2011-11-18 CY CY20111101116T patent/CY1112353T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CR10019A (es) | Derivados de mestastina y sus usos | |
| ECSP099279A (es) | Derivados de metastina y sus usos | |
| CR8828A (es) | Derivados de metastina y utilizacion de los mismos | |
| MX2019007276A (es) | Composiciones y métodos para mejora o aumento de la producción de ifn tipo i. | |
| MX2021006912A (es) | Composiciones para la administracion de agentes terapeuticos y metodos de uso y fabricacion de las mismas. | |
| CL2008001123A1 (es) | Compuestos derivados de acido lipoico; formulacion farmaceutica que lo comprende; y uso en el tratamiento del cancer. | |
| CR20120026A (es) | Construcciones novedosas de proteína del virus de papiloma humano (hpv) y su uso en la prevención de la enfermedad por el hpv | |
| DOP2013000212A (es) | Formas cristalinas del dimetoxi-docetaxel y sus procedimientos de preparacion | |
| MX389052B (es) | Formulaciones de insulina de accion prolongada. | |
| GT200500155A (es) | Terapia del càncer resistente al platino | |
| UY31543A1 (es) | Sistema de administracion de rnai de interferencia y usos del mismo | |
| DOP2009000178A (es) | Formulaciones para el tratamiento del cancer | |
| BR112015019064A8 (pt) | uso de uma composição compreendendo nanopartículas compreendendo paclitaxel e uma albumina para o tratamento de melanoma e kit | |
| MX2020002823A (es) | Fluorofenil beta-hidroxietilaminas y su uso en el tratamiento de la hiperglucemia. | |
| CL2008001373A1 (es) | Compuestos derivados de fenilamino-benceno sustituidos; metodo de preparacion; composicion farmaceutica; kit farmceuticos; y uso de dichos compuestos en el tratamiento del cancer. | |
| PA8584001A1 (es) | Indol-3-carboxamidas como activadores de glucoquinasa (gk) | |
| MX2015011445A (es) | Compuestos y usos de estos para la modulacion de la hemoglobina. | |
| ES2527454T3 (es) | El uso de derivados del péptido Wnt5-a para el tratamiento de melanoma y cáncer gástrico | |
| CR11814A (es) | Derivados de azacarbolinas, su preparacion y su utilizacion terapeutica | |
| AR077371A1 (es) | DERIVADOS DE PIRAZOL, SU PREPARACIoN Y SU APLICACIoN EN LA TERAPIA DEL CÁNCER | |
| CL2007001748A1 (es) | Compuesto derivado de 2-arilamino-4-aminopirimidinas, inhibidores de la proteina quinasa c-alfa; composiciones farmaceuticas que los contienen; y su uso para tratar o prevenir la diabetes, el cancer, enfermedades cardiovasculares y otras. | |
| PE20191836A1 (es) | Compuesto de insulina acilada | |
| MX390837B (es) | Composiciones de proteinas estables. | |
| CY1118975T1 (el) | Παραγωγο μεταστινης και χρηση αυτου | |
| CL2012003119A1 (es) | Composicion farmaceutica para inyeccion que compende una solucion acuosa de ibuprofeno y trometamol, en que la concentracion de ibuprofeno esta entre 2 y 6 mg/ml, la concentracion de trometamol esta entre 1.8 y 5.8 mg/ml, y el ph esta entre 7,0 y 9,5; y su uso para el tratamiento del dolor, la inflamacion o la fiebre. |